1. Home
  2. OI vs RCKT Comparison

OI vs RCKT Comparison

Compare OI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$14.74

Market Cap

2.0B

ML Signal

HOLD

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

HOLD

Current Price

$3.24

Market Cap

340.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
RCKT
Founded
1903
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
340.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OI
RCKT
Price
$14.74
$3.24
Analyst Decision
Buy
Buy
Analyst Count
7
14
Target Price
$16.29
$29.12
AVG Volume (30 Days)
2.9M
2.0M
Earning Date
02-03-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,455,000,000.00
N/A
Revenue This Year
$1.41
N/A
Revenue Next Year
$1.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.23
$2.19
52 Week High
$16.04
$13.35

Technical Indicators

Market Signals
Indicator
OI
RCKT
Relative Strength Index (RSI) 58.75 46.08
Support Level $15.00 $3.30
Resistance Level $15.34 $3.57
Average True Range (ATR) 0.48 0.18
MACD 0.03 -0.01
Stochastic Oscillator 62.18 22.81

Price Performance

Historical Comparison
OI
RCKT

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: